Serological Science for COVID-19 SeroNet
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 75N91019D00024-P00025-759102000003-43
Grant search
Key facts
Disease
COVID-19Start & end year
20202023Known Financial Commitments (USD)
$678,192Funder
National Institutes of Health (NIH)Principal Investigator
LEONARD FREEDMANResearch Location
United States of AmericaLead Research Institution
LEIDOS BIOMEDICAL RESEARCH, INC.Research Priority Alignment
N/A
Research Category
Pathogen: natural history, transmission and diagnostics
Research Subcategory
Pathogen morphology, shedding & natural history
Special Interest Tags
N/A
Study Type
Unspecified
Clinical Trial Details
N/A
Broad Policy Alignment
Pending
Age Group
Unspecified
Vulnerable Population
Unspecified
Occupations of Interest
Unspecified
Abstract
In light of the emergence of the novel coronavirus, SARS-CoV-2, and the urgent need to mitigate the pathogen's spread. There is a crucial need for accurate laboratory-based methods for initial diagnosis, asymptomatic carriage and overall public health understanding of the extent of this disease. The current lack of validated and widely available standardized tests, procedures and reagents for assessment of SARS-CoV-2-specific antibody responses is a critical gap in the rapid response to the SARS-CoV-2 pandemic. a major goal and focus of SeroNet is determining the molecular and cellular components of the immune response to SARS-CoV-2 to understand the innate, humoral and adaptive response, as well as to understand barriers to access